Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists test how experimental drug hooks into lung protein

NCT ID NCT07362290

First seen Jan 31, 2026 · Last updated Jun 23, 2026 · Updated 19 times

Summary

This study looks at how an experimental drug called XBD173 attaches to a protein (TSPO) in the lungs of 16 healthy volunteers. Using PET scans, researchers will measure how much of the drug is needed to block the protein and whether food affects drug levels. The goal is to gather basic information for future research on lung diseases.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS - MALE AND FEMALE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • NIHR Imperial CRF

    London, W12 0HS, United Kingdom

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

XBD173

What this could lead to

If successful, this could help design future studies on TSPO's role in lung diseases like pulmonary arterial hypertension.

What could go wrong

This is a very early, small study in healthy volunteers, not patients. It only measures drug binding, not any treatment effect, so it may not lead to any therapy.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.